Pfizer’s values and commitment to long-term sustainability through ESG goals are at the heart of the way we strive to responsibly live our purpose – breakthroughs that change patients’ lives.
2021 ESG Highlights
As planetary health impacts public health, we are committed to limiting our impact on the environment and the climate. Our company purpose – breakthroughs that change patients’ lives – guides our environmental priorities, with a focus on impact reduction, conservation of resources and the reduction of waste arising from our operations. As a global biopharmaceutical company, we are committed to applying science to fight the challenges posed by the climate crisis and innovating to bring products to the market that tackle health conditions linked to our warming planet.
Reduction in scope 1 and 2 greenhouse gas (GHG) emissions from 2019 baseline
Consecutive year on CDP’s Supplier Engagement Leaderboard
Reduction in water withdrawal and 13% reduction in hazardous and non-hazardous waste disposed compared to 2020
The COVID-19 pandemic continues to introduce uncertainty and fluid challenges, heightening our business imperative to harness scientific innovation to help create a healthier, more equitable world for all. While we are continually redoubling our efforts to address COVID-19 as it evolves, we remain focused on helping to address the burden on individuals, their families, and communities of other equally debilitating infectious and chronic diseases. Through our partnerships and programs, we aim to expand affordable access to our breakthrough medicines and vaccines, particularly among underserved communities. Our societal priorities extend to people across the globe and within our own workforce and supply chain, as we invest in our human capital and work to advance diversity, equity, and inclusion.
Estimated patients 1 treated or vaccinated by a Pfizer product (424m excluding COVID-19 vaccines or treatments)
Representation for women globally and 25% for U.S. minorities at VP+ levels
Clinical success rate (first-inhuman to approval) for Pfizer new molecular entities by end of 2021
Patient counts are estimates based on multiple data sources.
We behave ethically and thoughtfully in everything that we do, owning our responsibility to change lives for the better. As part of this responsibility, Pfizer prioritizes safety, quality, and transparency in our operations. Our governance structure supports proactive business-led quality and compliance built around elements of effective risk management. To facilitate accountability, our Board of Directors is more involved than ever in the governance and implementation of our ESG strategy. This board is made up of diverse representatives with respect to gender, age, race, ethnicity, background, and professional experience and a majority of independent directors.
Members of Board of Directors are female
Members of Board of Directors identify as ethnically diverse
Named one of the World’s Most Ethical Companies by Ethisphere*
* “World’s Most Ethical Companies” and “Ethisphere” names are registered trademarks of Ethisphere LLC.